Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 5
1995 6
1996 9
1997 9
1998 17
1999 14
2000 16
2001 27
2002 22
2003 20
2004 20
2005 16
2006 17
2007 11
2008 9
2009 7
2010 9
2011 17
2012 12
2013 11
2014 12
2015 21
2016 22
2017 18
2018 17
2019 18
2020 17
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

372 results
Results by year
Filters applied: . Clear all
Page 1
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Among authors: raderer m. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Zucca E, et al. Among authors: raderer m. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. Ann Oncol. 2020. PMID: 31912792 Free article. No abstract available.
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Yao JC, et al. Among authors: raderer m. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703889 Free PMC article. Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Among authors: raderer m. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Marginal Zone Lymphomas.
Bertoni F, Rossi D, Raderer M, Zucca E. Bertoni F, et al. Among authors: raderer m. Cancer J. 2020 Jul/Aug;26(4):336-347. doi: 10.1097/PPO.0000000000000463. Cancer J. 2020. PMID: 32732678 Review.
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Among authors: raderer m. Endocr Relat Cancer. 2016 Mar;23(3):191-9. doi: 10.1530/ERC-15-0490. Epub 2016 Jan 7. Endocr Relat Cancer. 2016. PMID: 26743120 Free PMC article. Clinical Trial.
How I treat neuroendocrine tumours.
Kiesewetter B, Raderer M. Kiesewetter B, et al. Among authors: raderer m. ESMO Open. 2020 Aug;5(4):e000811. doi: 10.1136/esmoopen-2020-000811. ESMO Open. 2020. PMID: 32817134 Free PMC article. Review.
The multiple faces of marginal zone lymphomas.
Raderer M. Raderer M. Hematol Oncol. 2017 Jun;35 Suppl 1:46-48. doi: 10.1002/hon.2400. Hematol Oncol. 2017. PMID: 28591419 Review. No abstract available.
372 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page